CHANGES OF BIOCHEMICAL PARAMETERS OF RABBITS BLOOD DURING EXPERIMENTAL TOXIC HEPATITIS UNDER THE INFLUENCE OF TIMOCIN

CHANGES OF BIOCHEMICAL PARAMETERS OF RABBITS BLOOD DURING EXPERIMENTAL TOXIC HEPATITIS UNDER THE INFLUENCE OF TIMOCIN

1Rajabov F.F., 2Shahmatov A.N., 3Hudoidodov B.

CHANGES OF BIOCHEMICAL PARAMETERS OF RABBITS BLOOD DURING EXPERIMENTAL TOXIC HEPATITIS UNDER THE INFLUENCE OF TIMOCIN

1laboratory affairs course in the State Educational Establishment «Institute of Postgraduate Education in Health Sphere of Republic of Tajikistan»

2Laboratory LLC «Zand», Dushanbe

3Center of forensic-medical expertise, Dushanbe

Aim. Assess the biochemical indices of animals blood at experimental toxic hepatitis caused carbon tetrachloride.

Materials and methods. Investigations were performed on 10 outbred rabbits a mass 2-3 kg with standard diet and content. Toxic hepatitis was induced by introducing to animals of carbon tetrachloride in admixture with vegetable oil (1: 1) in an amount of 2 ml for 10 days once per day.

For research was used immunomodulatory drug timocin (26092014 series, valid until 26.09.2014, the manufacturer LLC «Tib Baroi shumo», Tajikistan). Timocin was injected to animals after injection of carbon tetrachloride for 10 days once a day at a dose of 0.01 ml per 1 kg of animal body weight.

Before administration and after administration in the blood serum determined the: total protein content, cholesterol, bilirubin (total, bound and free), urea, creatinine, glucose, triglycerides, HDL cholesterol, uric acidactivity of enzymes ALT, AST, and amylase).

Results. The introduction of carbon tetrachloride contributed to the development of toxic hepatitis in rabbits, which was confirmed by a considerable increase of bilirubin, ALT and AST activity. After applying of timocin the positive dynamics of changed biochemical indices: significantly reduces the content of bound and free bilirubin, which led to the normalization of total bilirubin. ALT and AST also falls below the physiological norm.

Conclusion. Application of timocin normalize the content of bilirubin, glucose, cholesterol, ALT and AST activity, which indicates the presence of hepatoprotective properties in it.

RESERENSES

1.  Bobiev G. M., Bunyatyan N. D. Immunoaktivnye peptidy i ikh koordinatsionnye soedineniya v meditsine [Immunoactive peptides and their coordination compounds in medicine]. Moscow, Russkiy vrach Publ., 2009. 239 p.

2.  Zemskov A. M. Klinicheskaya immunologiya: uchebnoe posobie dlya studentov meditsinskikh vuzov [Clinical immunolo­gy: manual for students of medical universities]. Moscow, GEO­TAR-Media Publ., 2005. 320 p.

3.  Mansurov Kh. Kh., Mirodzhov G. K., Mansurova F. Kh., Bobiev G. M., Kholnazarov B. M. Timotsin v terapii khronicheskikh diffiaznykh zabolevaniy pecheni [Timocin in the treatment of chronic diffuse liver diseases]. Problemy gastroenterologii — Problems of gastroenterology, 2010, No. 1-2, pp. 40-49.

4.  Morozov V G., Khavinson V Kh., Malinin V V Peptidnye timomimetiki [Peptide timomimetiks]. St. Peterburg, Nauka Publ., 2000. 158 p.

5.  Okovityy S. V, Gayvoronskaya V V Immunnye mekh- anizmy realizatsii gepatoprotektornykh effektov etomerzola i timogena [Immune mechanisms of realization of hepatoprotective effects of etomerzol and timogen]. Eksperimentalnaya i klinich­eskayafarmakologiya — Experimental and Clinical Pharmacology, 2002, No. 3, pp. 58.

6.  Radchenko V. G., Shabrov A., Zinoveva E. N. Osnovy klinicheskoy gepatologii. Zabolevaniya pecheni i biliarnoy sistemy [Fundamentals of Clinical Hepatology. Liver and biliary system]. Moscow, BINOM Publ., 2005. 864 p.

7.  Tsukerman A. Dzh., Lavanchi D. [Options for the treatment of chronic hepatitis — perspectives of the use of antiviral drugs]. Mezhdunarodnyy Meditsinskiy Zhurnal. (In Russ.) Available at: http:// www.medlinks.ru

8.  Yunkerov V I., Grigorev S. T Matematichesko-statistich- eskaya obrabotka dannykh meditsinskikh issledovaniy [Mathemat­ical and statistical processing of medical research]. St. Peterburg, Voenno-meditsinskaya akademiya Publ., 2002. 266 p.

9.  Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clinical Gastroenterology Hepatology, 2004, No. 2, pp. 1048-58.

10.  De Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. Journal of Hepatology, 2008, Vol. 48, Suppl. 1, pp. 104-112.

Комментарии

Back to Top